FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

<b>STATEMENT</b>	<b>OF CHANGES</b>	IN BENEFICIAL	<b>OWNERSHIP</b>

ı	OMB APPRO	VAL				
	OMB Number:	3235-0287				
l	Estimated average burde	en				
	hours per response:	0.5				

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

								,											
1. Name and Address of Reporting Person* WENDER JOSEPH H						2. Issuer Name <b>and</b> Ticker or Trading Symbol ISIS PHARMACEUTICALS INC [ ISIS ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director 10% Owner					
	`	First) .CEUTICALS, I .D ROAD	(Middle)		0	3. Date of Earliest Transaction (Month/Day/Year) 06/30/2008  4. If Amendment, Date of Original Filed (Month/Day/Year)								Director Officer (give title below)		Other (sp below)		pecify	
(Street) CARLSI	BAD C	A	90008		-   *. -									Form file	iled by One Reportin		ting Person		
(City)	(5	State)	(Zip)																
		Ta	able I - Noi	1					quired,	Dis	1	-		1					
1. Title of Security (Instr. 3)  2. Trans. Date (Month/I				action 2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr.			nd 5) Securities Beneficially Owned Following		Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership						
									Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
Common Stock 06/30,					30/20	0/2008 06/30/2008		M		4,000(1)	,000 <sup>(1)</sup> A \$		35,000			D			
			Table II -								osed of, o			wned				•	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	ate Execution Date,	Code (Instr					6. Date Exercisable and Expiration Date (Month/Day/Year)		9	7. Title and of Securiti Underlying Derivative (Instr. 3 ar	es J Security	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficia Owned Following Reported	re (es lally lally (es lally lally (es lally lall) (es lally (es lall) (es l	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				C	Code	v	(A)	(D)	Date Exercisal	ble	Expiration Date	Title	Amount or Number of Shares		Transaction(s (Instr. 4)	on(s)	<u>'</u>		
Director Stock Option (right to buy)	\$13.25	06/30/2008	06/30/200	8	M			4,000	07/01/20	)02	06/30/2008	Common Stock	4,000(1)	\$0	0		D		
Director Stock Option (right to	\$13.88	07/01/2008	07/01/200	8	A		15,000		07/01/200	)9 <sup>(2)</sup>	06/30/2018	Common Stock	15,000	\$0	15,00	0	D		

## **Explanation of Responses:**

- 1. Result of exercising a stock option that was scheduled to expire on 6-30-08.
- 2. Grant of 7-1-08 to reporting person of stock options under the Isis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in four equal annual installments, with the first installment vesting on 7-1-09. The option shall be fully vested and exercisable on 7-1-12. The option is exercisable as to 0 shares on 7-1-08.

## Remarks:

/s/B. Lynne Parshall, Attorneyin-Fact 07/01/2008

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.